105 results about "Liver fat" patented technology

The invention relates to the technical field of medical image recognition, in particular to a fat content analysis method and system based on a liver pathological section image, and the method comprises the following steps: extracting a liver fat vacuole gravity center sequence, recognizing and arranging mutation nodes, removing abnormal vacuoles, analyzing a boundary structure, extracting a closed boundary, and generating a fat content analysis result. According to the method, through selection of the adjacent pixel group of the structure edge in the fat cavitation region and construction of the gravity center sequence, deep characterization of the fat cavitation arrangement characteristics is realized, and stable reference is provided for subsequent structure identification; abnormal change nodes are identified based on an evolution trend of an included angle of adjacent gravity center vectors in the gravity center sequence, arrangement direction mutation points are effectively positioned, impurity interference is screened out, and misjudgment of fat assessment caused by irregular accumulation is avoided; by means of calculation of a gravity center drift curve and a compactness variable coefficient, a form fluctuation area is recognized, abnormal cavitation bubbles are removed, and the consistency and stability of structure extraction are enhanced.

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

The application discloses a method for simulating a magnetic resonance signal of fatty liver tissue, which comprises the following five steps: obtaining a proton density fat fraction (PDFF) and an effective transverse relaxation rate parameter of the fatty liver tissue; and the method has the beneficial effects that: a three-dimensional simulation model of the fatty liver tissue with different fat fractions is simulated, the PDFF and the predicted value corresponding to the fat fraction are obtained, and thus a correction relationship between the fat fraction and the parameter is established; meanwhile, by adjusting the parameters (magnetic field strength, etc.) in the three-dimensional simulation model of the fatty liver tissue, the influence of fat on the parameter can be corrected in different scenes; and the method can improve the quantification accuracy of liver iron and liver fat through the correlation between the fat fraction and the parameter.

The invention belongs to the technical field of microorganisms, and provides lactobacillus (Ligilbacillus sp.) RG-A helpful for reducing blood fat and application of the lactobacillus (Ligilbacillus sp.) RG-A. The lactobacillus (Ligilbacillus sp.) RG-A is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.33967. The lactobacillus (Ligilbacillus sp.) RG-A has the advantages that the lactobacillus (Ligilbacillus sp. The lactobacillus provided by the invention has good acid resistance and cholate resistance, the survival rate is 74% under the condition of pH 3.0, and the survival rate is 38% under the condition of 0.3% cholate; animal experiments show that the lactobacillus provided by the invention can be applied to preparation of various products for retarding weight gain and improving dyslipidemia and liver fat deposition, and has important clinical application value and industrialization prospect.

The invention relates to an intestinal flora derivative indolepropionic acid capable of relieving obesity and application thereof, and discloses new application of indolepropionic acid in obesity treatment. Indolepropionic acid is prepared through a microbial fermentation method, the purity is higher than that of indolepropionic acid prepared through a chemical synthesis method, multi-target metabolism regulation is achieved by activating a PPAR-gamma signal channel, and the effects of fat metabolism remodeling, liver injury repairing, glycometabolism regulation, inflammation inhibition and the like are achieved; compared with the prior art, the probiotic strain dependence is broken through, a single and definite active component, namely indolepropionic acid, is provided, and the complexity and effect fluctuation of flora intervention are eliminated; the multi-target metabolism regulation is realized, the increase of white fat browning and the reduction of liver fat decomposition are synchronously promoted, and the problem that the fat type cannot be converted by the existing metabolite is solved; the industrial feasibility is optimized, the high-purity indolepropionic acid is prepared through microbial fermentation, the cost is reduced compared with that of a chemical synthesis method, and the purity and production cost bottlenecks are broken through.

The present invention discloses the preparation of plantain polysaccharide and its application in the preparation of drugs for preventing and treating fatty liver and hemorrhagic syndrome in laying hens, belonging to the field of biomedicine technology. The present invention also provides the application of plantain polysaccharide in the preparation of feed additives for regulating and / or treating fatty liver in laying hens. The present invention comprehensively explores the preventive and therapeutic effects of different doses of plantain polysaccharide on fatty liver in laying hens induced by high-energy and low-protein diets through in vitro and in vivo experimental modeling and detection of relevant indicators, and reduces liver fat deposition by regulating liver fat synthesis and oxidative catabolism and ferroptosis-related signaling pathways, thereby effectively preventing and treating fatty liver and hemorrhagic syndrome in laying hens induced by high-energy and low-protein diets. The present invention also studies the preventive and therapeutic effects of plantain polysaccharide on egg production and fatty liver in laying hens, and concludes that plantain polysaccharide can increase egg production in laying hens and improve production performance.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

The application relates to the technical field of medical treatment and discloses a liver chronic disease screening method, a device and a storage medium.The method comprises the following steps: a liver detection system collects liver stiffness data and liver fat attenuation parameters of a target object; a mobile terminal system receives the liver stiffness data and the liver fat attenuation parameters, combines the liver stiffness data and the liver fat attenuation parameters with basic information of a preset target object, generates acquisition characteristic data, carries out label marking matrix processing on pretreatment integrated data of the cloud service system, generates a label marking matrix, carries out fitting residual processing on the label marking matrix, obtains extended decision tree data, carries out discrete sampling processing on the extended decision tree data, obtains a sparse vector, carries out classification calculation processing on the sparse vector, obtains a classification result, and generates a disease screening report based on the classification result.In the embodiment of the application, through system architecture and cloud service system data processing, the early warning timeliness and accuracy of liver chronic disease screening are improved.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

The invention discloses a scatophagus argus liver fat storage cell separation and culture method, and belongs to the technical field of cell biology. According to the present invention, the scatophagus argus liver fat storage cells are obtained through separation by using a perfusion method, and then the scatophagus argus liver fat storage cells obtained through separation are cultured by using a DMEM medium sugar culture medium containing 8-12% of FBS, 4-6% of HBS, 0.005-0.015% of HGF, 0.005-0.015% of HGP, 0.12-0.16 nM of vitamin A acid and 2-2.5 mM of L-glutamine; the ITO cells obtained through separation can be normally cultured to five generations, and the cells have good cell viability.

The present invention discloses a fully automatic ultrasound liver fat content detection method and system based on double Nakagami, comprising: S1. acquiring B-mode images of an ultrasound liver and IQ envelope data of an original RF signal; S2. performing image segmentation on the B-mode image using a deep learning segmentation method to segment out the liver parenchyma and vascular regions in the image; S3. post-processing the image segmentation results to obtain a candidate curved-edge trapezoidal ROI region containing only the liver parenchyma; S4. inputting the IQ envelope signal position area data corresponding to the candidate ROI region into a double Nakagami mixed distribution model, and estimating and optimizing the model parameters through an algorithm to obtain the fat content in the specified ROI region; the present invention realizes fully automatic quantitative detection of ultrasound liver fat content, which helps doctors or users complete the detection of liver fat content without relying on ultrasound clinical knowledge.

1. The name of the design product: liver fat measuring instrument. 2. The use of the design product: for detecting and evaluating liver fat. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention discloses application of an Fn1-PPARbeta / delta signal channel related to a cardiac liver disease. The cardiac liver disease model is constructed according to the conditions that the liver development of young individuals is delayed due to heart injury and both adult and young individuals have serious fatty livers. In the model, the Fn1 protein level in the heart and blood is obviously increased compared with the normal level. Based on a zebra fish heart ablation means, after heart ablation injury, the heart specific knock-down Fn1 can lead to reduction of the Fn1 protein level in blood and alleviation of liver development retardation and fat deposition. Through the screening of transcriptomics, the PPARbeta / delta protein in the liver is found to be a potential downstream effect factor of Fn1. The liver specific overexpression PPARbeta / delta protein can significantly relieve abnormal phenotypes such as liver fat deposition caused by heart injury, and after the liver specific knock-down PPARbeta / delta protein, the protection effect of knock-down Fn1 on the liver disappears under the condition of heart injury. Therefore, the Fn1 protein and the PPARbeta / delta protein can be used as targets for preventing and treating the cardiac liver injury, and are used for preparing medicines for improving the cardiac liver injury, so that a new way is provided for treating the cardiac liver disease.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention comprises astragalus membranaceus, cinnamon, semen cassiae, lotus leaves, poria cocos, lophatherum gracile, malt, hawthorn, rose, pogostemon cablin, sophora flower, semen torreya and emblic leafflower fruit. The formula takes the effects of tonifying spleen and promoting diuresis, soothing liver and regulating qi, and removing food retention and dissolving turbidity as the core, and has multiple effects of promoting urination and relieving stasis. The traditional Chinese medicine composition provided by the invention can regulate and control abnormal signal pathways of fatty liver and atherosclerosis; the compound has no obvious inhibition effect on a hepatic cell line HepG2 and has an inhibition effect on a hepatic stellate cell line LX2; the obvious lipid-lowering effect is achieved on a HepG2 high-lipid model; liver fat accumulation and liver injury in a TAA-induced zebrafish fatty liver model can be remarkably improved.

The invention belongs to the technical field of microbial fermentation protease, and particularly relates to application of nattokinase in preparation of a medicine for relieving alcoholic liver injury diseases. The nattokinase disclosed by the invention can be used for effectively relieving the increase of the liver-weight ratio of mice caused by alcohol; meanwhile, nattokinase can improve liver fat accumulation induced by alcohol; hepatocyte arrangement orderliness is recovered, and inflammatory cell infiltration is reduced; the antioxidant capacity can be improved, and the condition of liver function damage can be relieved; and the effect of recovering the normal liver blood fat level is achieved.

The invention discloses a preparation method and application of cannabis sativa peptide with effects of reducing blood fat and adjusting lipid metabolism, belongs to the technical field of biology, and has a wide application prospect. The fructus cannabis peptide obtained by the technical scheme and the preparation method disclosed by the invention has the following effects: 1, the fructus cannabis peptide prepared by the preparation method disclosed by the invention can be used for remarkably improving pancreatic lipase activity (the highest inhibition rate can reach 65.0%), so that digestion and absorption of a human body on lipid substances such as animal and vegetable oil and cholesterol are blocked; 2, the cannabis sativa peptide prepared by the preparation method disclosed by the invention can be used for remarkably improving the abnormality of four items of blood fat, reducing the level of total cholesterol, triglyceride and low-density lipoprotein and remarkably improving the level of high-density lipoprotein; 3, the prepared cannabis sativa peptide can obviously relieve non-alcoholic fatty liver disease caused by obesity and reduce liver fat accumulation; 4, the cannabis sativa peptide prepared by the invention can effectively relieve the occurrence and progress of obesity, reduce the weight change rate and reduce the obesity index, and has good lipid-lowering and weight-losing effects.

The invention discloses saposhnicovia divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of natural polymers. The method has the advantages that the average relative molecular weight is measured through GPC, monosaccharide composition is analyzed through GC-MS, it is found that the average relative molecular weight of the saposhnicovia divaricata polysaccharide RSP-1 is 111125 Da, the protein content of the saposhnicovia divaricata polysaccharide RSP-1 is 1.29%, the saposhnicovia divaricata polysaccharide RSP-1 does not contain uronic acid and is neutral polysaccharide, and it is found that trace beta-pyranose exists. Meanwhile, the saposhnicovia divaricata polysaccharide RSP-1 disclosed by the invention can be used for remarkably relieving liver fat infiltration, reducing the number of ballooning and necrotic cells and relieving alcoholic liver injury.

The invention provides a composition for relieving fatty liver and application thereof, and belongs to the technical field of medicines. The composition disclosed by the invention is prepared from the following components: dihydroberberine, neoruscogenin, hispidulin and trans-trimethoxy resveratrol, wherein the final concentration of the dihydroberberine, the final concentration of the neoruscogenin, the final concentration of the hispidulin and the final concentration of the trans-trimethoxy resveratrol are all 5 to 15 [mu] M. The composition disclosed by the invention can be used for effectively relieving liver fat accumulation, liver function damage and liver oxidative stress injury, and has a good application prospect as a new product for preventing and controlling the fatty liver.

The present application belongs to the field of nutritional composition and biological medicine technology, and particularly relates to a composition for protecting and preserving liver, a preparation method, application and product thereof. The composition of the present application is composed of extract of Silybum marianum, glucoraphanin and extract of Cynara scolymus. The composition of the present application can intervene the pathological process of liver injury from multiple dimensions such as antioxidation, anti-inflammation, regulation of lipid metabolism and repair of hepatocytes through synergistic effect of the three components, significantly reduces the levels of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, reduces the accumulation of liver fat, improves the antioxidant capacity of the body, effectively prevents or improves alcoholic, chemical, non-alcoholic fatty and autoimmune liver injury, delays the progression of liver fibrosis, and comprehensively maintains the structural integrity and functional stability of the liver.

A method for preventing or treating metabolic diseases includes administering a composition including a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof. Thereby, it is possible to inhibit increases in body weight and liver fat weight due to a high-calorie diet, and decrease an accumulation of fat in the liver tissue, as well as modulate gene expression related to fat metabolism, and ultimately exhibit excellent preventive and therapeutic effects on metabolic diseases.

The invention discloses a fermented sausage source active peptide as well as a preparation method and application thereof in preparation of medicines for preventing and treating alcoholic liver injury, and belongs to the technical field of biological medicines. The amino acid sequence of the fermented sausage source active peptide comprises one or more of WLKLRPILK and RGPPRPRPAPA. The method disclosed by the invention has the beneficial effects that the bioactive peptide can be efficiently extracted from the minced pork within a relatively short time. The active peptide has a remarkable relieving advantage on alcoholic liver injury, and can inhibit liver fat synthesis increase caused by alcohol intake and promote catabolism of fatty acid through an AMPK pathway. And a peptide fragment with an AMPK activation effect is rapidly screened through computer screening and molecular docking. The method has high reference value for low-cost preparation of the fermented meat-derived active peptide and prevention of alcoholic liver injury, and is suitable for popularization and application.

The present invention relates to a construction method for preparing a mouse model of non-alcoholic steatohepatitis by infecting with Helicobacter muridarum, which is characterized by abnormal serum liver function, infiltration of inflammatory cells in the liver, liver fat deposition, ballooning degeneration, and fibrosis, etc., and is a non-alcoholic steatohepatitis animal model caused by a high-fat diet and intraperitoneal injection of Helicobacter muridarum. BALB / c mice are selected and randomly divided into a control group, a high-fat diet group, a Helicobacter muridarum infection group, and a high-fat diet combined with Helicobacter muridarum infection group. The body weight of the mice is weighed once a week. After 14 and 22 weeks, blood is taken to prepare serum and liver function is detected, and at the same time the mice are sacrificed; fresh liver tissue is taken to determine the total triglyceride and total cholesterol content in the liver, and liver tissue sections are prepared for H&E, Oil Red O, and Sirius red staining to judge the effect of the NASH model. Through the present invention, it can provide a good animal model for the research and development of new drugs for NASH, and also provide a convenient animal model for studying the mechanism of intestinal microorganisms in the pathogenesis of NASH.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The present invention provides a compound for use in reducing liver fat in a subject, wherein the compound is selected from:(i) (R)-3-hydroxybutyrate;(ii) an ester of (R)-3-hydroxybutyrate; and(iii) an oligomer obtainable by polymerising (R)-3-hydroxybutyrate moieties;or a pharmaceutically acceptable salt or solvate thereof. The compound is particularly useful in subjects suffering from a fatty liver. The compound can be used to treat non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) or non-alcoholic fatty liver (NAFL).

The invention relates to the field of medical preparations, in particular to application of ingenol in preparation of a medicine for treating liver injury of postmenopausal women. The ingenol intervenes in OVX to induce a postmenopausal obese mouse, and the ingenol is proved to be capable of remarkably reducing the weight and fat content of the mouse, reducing serum TC, TG and LDL-c level rise, improving hepatocyte swelling and reducing the number of liver fat droplets, and also capable of remarkably reducing serum AST and ALT level rise caused by OVX and relieving liver injury induced by OVX. Therefore, the ingenol can be used for effectively treating the liver injury of the postmenopausal women, and can be used for preparing a medicine for treating the liver injury of the postmenopausal women and a medicine for reducing the level of a liver injury marker in serum. The method can provide a new direction and strategy for future development and application of ingenol.

Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TGR5. The bile acid derivative of the present invention inhibits or delays the metabolism of bile acid by bacterial BSH / 7α dehydroxylase in the intestine and greatly prolongs the effective survival time of bile acid in the intestine. The bile acid derivative and the pharmaceutical composition thereof can significantly stimulate bile acid membrane receptor TGR5, promote the secretion of glucagon-like peptide 1 from enteroendocrine cells, reduce liver fat accumulation, significantly improve liver function and increase glucose tolerance, thereby having an excellent effect on the treatment of fatty liver disease.

A patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention finds that the cyclic peptide has the effect of reducing body weight. The invention is named as application of the polypeptide COX52-69 in reducing liver fat accumulation and fat cell volume. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can reduce liver fat accumulation and reduce the fat cell volume of fat tissue while reducing the weight of the DIO mouse. Therefore, the COX52-69 cyclic peptide has practical application in improving the volume of the fatty liver and the fat cells.